By selecting the Yes option, leaving Amgen.eu option you understand that you are leaving the corporate page of Amgen Europe and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen discovers, develops, produces and supplies innovative medicines for patients suffering from serious illnesses. We support health care professionals and patients in the administration and optimization of our innovative therapies.
Below you can see the medicines available in the Saudi Arabia:
A physician may prescribe AMGEVITA for the treatment of various inflammatory diseases. AMGEVITA contains the active ingredient adalimumab. Amgevita is used for the treatment of: Rheumatoid Arthritis
Click here to learn more
Aranesp is used for treatment of symptomatic anemia associated with chronic renal failure (CRF) in adults and pediatric patients (see section 4.2).
Treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy
BLINCYTO is indicated for the treatment of MRD-positive B-cell precursor ALL BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission (CR) with minimal residual disease (MRD) greater than or equal to 0.1%. Relapsed or refractory B-cell precursor ALL BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), Refer to SMPC for full information.
Click here to learn more
EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
Click here to learn more
Evenity API
Osteoporosis Management Guide
Breast cancer: Metastatic breast cancer, KANJINTI is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC).
Early breast cancer: KANJINTI is indicated for the treatment of adult patients with HER2-positive early breast cancer (EBC).
KANJINTI should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
Metastatic gastric cancer: KANJINTI in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
KANJINTI should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.
Kyprolis is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who has received one to three lines of therapy in combination with: Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone.
Kyprolis is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who has received one or more lines of therapy
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an approved test, who have received at least one prior systemic therapy.
Click here to learn more
Mimpara is used (in adults):
Mimpara is used in children aged 3 years to less than 18 years of age: to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.
MVASI in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum, MVASI in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. MVASI in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with MVASI in combination with capecitabine, MVASI, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. MVASI, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR) activating mutations, MVASI in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. MVASI, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer, MVASI, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. MVASI in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents, MVASI, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.
Nplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g., corticosteroids, immunoglobulins).
Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in pediatric patients one year of age and older who are refractory to other treatments.
Psoriatic arthritis
Otezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
Psoriasis
Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
Behçet’s disease
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy
Click here to learn more
Parsabiv is used to treat secondary hyperparathyroidism in patients with serious kidney disease who need hemodialysis to clear their blood of waste products.
Prolia is used as:
Click here to learn more
Prolia API
Osteoporosis Management Guide
Repatha is indicated in adults with primary hypercholesterolemia (heterozygous familial and non‑familial) or mixed dyslipidemia, and in pediatric patients aged 10 years and over with heterozygous familial hypercholesterolemia, as an adjunct to diet:
For study results with respect to effects on LDL-C, cardiovascular events and populations studied
Click here to learn moreTepezza is indicated for the treatment of thyroid eye disease, Tepezza is an insulin-like growth factor-1 receptor inhibitor, is a fully human IgG1 monoclonal antibody produced in Chinese hamster ovary cells.
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal
cancer (mCRC)
Xgeva is used in Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.
Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.